Clinical trials: sponsored by Jonsson Comprehensive Cancer Center
Younger Breast Cancer Survivors
A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors
Younger women with breast cancer experience substantially greater distress and depressive symptoms than older women. These symptoms can hamper recovery and healthy behaviors that can reduce the risk of recurrence and/or other…
- Trial name
- NCT01558258
- Testing
- Mindful Awareness practices (MAPs)
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors
There are over 2 million breast cancer survivors in the US today. Along with extended survival, many women experience short and long-term after effects of treatment, which may decrease their quality of life and contribute to…
- Trial name
- NCT01540955
- Testing
- Improving Cognition with group intervention
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Inserting the gene for interleukin-2 into a person's prostate cancer cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00005072
- Testing
- Leuvectin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vical
Prostate Cancer
Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer.
- Trial name
- NCT00004050
- Testing
- Leuvectin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Vical
Kidney Cancer
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00301990
- Testing
- aldesleukin, bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease
RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo…
- Trial name
- NCT00005024
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin)
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070343
- Testing
- oblimersen sodium, dacarbazine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004979
- Testing
- paclitaxel, topotecan hydrochloride
- Sponsor
- Jonsson Comprehensive Cancer Center
Myelodysplastic Syndromes
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Monoclonal antibodies such as gemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00022321
- Testing
- gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00040950
- Testing
- rituximab, agatolimod sodium
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006084
- Testing
- lintuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as volociximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00278187
- Testing
- volociximab, erlotinib hydrochloride
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00096239
- Testing
- CP-547,632
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of solid tumors by stopping blood flow to the tumor.
- Trial name
- NCT00005996
- Testing
- cisplatin, gemcitabine hydrochloride, semaxanib
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00022685
- Testing
- epratuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Colorectal Cancer
SU006668 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer
- Trial name
- NCT00024063
- Testing
- orantinib
- Sponsor
- Jonsson Comprehensive Cancer Center
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ZD0473 in treating patients who have progressive or…
- Trial name
- NCT00021008
- Testing
- picoplatin
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin)
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00081042
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00042913
- Testing
- epratuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center